Activity Overview
Please read the following information about this continuing pharmacy education (CPE) activity before accessing the presentation using link located at the bottom of this page.
Release date: January 20, 2010 Expiration Date: January 31, 2011
Accreditation for Pharmacists
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity provides 2 hours (0.2 CEUs) of continuing pharmacy education credit (ACPE activity #204-000-09-437-H01P).
Methods and Format
This is an online activity consisting of audio, video, and slides for the presentation, a post-test, and an activity evaluation tool. Participants should claim continuing education credit for this internet-based educational activity only if they have not claimed credit for the live activity. Participants must view the entire presentation, take the activity post-test, and complete the course evaluation to receive continuing pharmacy education credit. A minimum score of 70% is required on the test for credit to be awarded, and participants may print their official statements of continuing pharmacy education credit immediately. The estimated time to complete this activity is 2 hours. This activity is provided free of charge.
Target Audience
This continuing pharmacy education activity was planned to meet the needs of all pharmacists, especially those who manage patients at risk for venous thromboembolism or who specialize in anticoagulation therapy.
Activity Content
Click here to view an overview of the activity content.
Learning Objectives
After participating in this knowledge-based CPE activity, participants should be able to
- Describe the scope of the problem of venous thromboembolism (VTE), including incidence, risk factors, clinical consequences, and impact on use of health care resources.
- Outline current evidence-based guidelines for primary prevention of VTE.
- Identify a quality improvement initiative for improving the use of anticoagulants in patients at risk for VTE.
- Compare and contrast the efficacy and safety of emerging anticoagulant agents and technologies for VTE prophylaxis.
- Identify unique patient characteristics that necessitate adjusting the traditional approach to VTE prophylaxis.
- Describe a management dilemma pertaining to the use of anticoagulants for VTE prophylaxis faced by health-system pharmacists and a potential solution to the dilemma.
- State the key issues that need to be considered when contemplating the addition of a new anticoagulant agent to the health-system formulary.
Faculty
Stuart T. Haines, Pharm.D., BCPS, FCCP, FASHP, FAPhA, Chair and Moderator
Professor and Pharmacotherapy Specialist
University of Maryland School of Pharmacy, Baltimore, Maryland
Clinical Specialist
West Palm Beach VA Medical Center, West Palm Beach, Florida
William E. Dager, Pharm.D., BCPS, FCSHP, FCCP, FCCM
Pharmacist Specialist
UC Davis Medical Center
Clinical Professor of Pharmacy
University of California, San Francisco, and Touro School of Pharmacy
Clinical Professor of Medicine
University of California, Davis
Sacramento, California
Toby C. Trujillo, Pharm.D., BCPS
Associate Professor
School of Pharmacy, University of Colorado Denver
Clinical Specialist – Cardiology/Anticoagulation
University of Colorado Hospital
Aurora, Colorado
Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Guidelines for Standards for Commercial Support, ASHP Advantage requires that all individuals involved in the development of activity content disclose their relevant financial relationships and that conflicts of interest be identified and resolved prior to delivery of the activity.
The faculty and planners report the following relationships:
Stuart T. Haines, Pharm.D., FCCP, FASHP, FAPhA, Chair and Moderator
Dr. Haines declares that he has been a stockholder (< $10,000) in Merck and that his spouse has served as a consultant for Procter & Gamble.
William E. Dager, Pharm.D., BCPS, FCSHP, FCCP, FCCM
Dr. Dager declares that he has no relationships pertinent to this activity.
Toby C. Trujillo, Pharm.D., BCPS
Dr. Trujillo declares that he has served as a consultant for Ortho-McNeil.
Kristi N. Hofer, Pharm.D.
Dr. Hofer declares that she has no relationships pertinent to this activity.
Launch Presentation*
The Changing Face of Anticoagulant Therapy: Improving the Management of Patients at Risk for Venous Thromboembolism (115 min)
*Allow additional time to complete the post-test and evaluation.
Download Post-Test
Click here to print the post-test for your reference. Please note that to be eligible for continuing pharmacy education credit, you must go to the ASHP Learning Center and complete the test online.
Additional Resources
For additional information about this topic or to sign-up to be notified when new resources are available, visit ww.ashpadvantage.com/vte/.
